NeurologyLive® Friday 5 — April 18, 2025

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Expanding Access to Whole Genome Sequencing in Parkinson Research: James Beck, PhD

The chief scientific officer of the Parkinson’s Foundation discussed the foundation’s efforts to integrate whole genome sequencing into PD GENEration and expand access across diverse global populations. [WATCH TIME: 4 minutes]

2: Adapting Cognitive Tools for Clinical Trials in Down Syndrome: Elizabeth Head, PhD

The professor in the Department of Pathology and Laboratory Medicine at the University of California, Irvine, gave clinical insights on efforts to refine neuropsychological outcome measures for individuals with Down syndrome at risk for Alzheimer disease. [WATCH TIME: 3 minutes]

3: Recognizing and Managing Paraneoplastic Neurological Syndromes: Ditte Primdahl, MD; Shailee Samir Shah, MD

A duo of neurology experts from Feinberg School of Medicine talked about the diagnostic challenges, evolving understanding, and clinical implications of paraneoplastic neurological syndromes. [WATCH TIME: 3 minutes]

4: NeuroVoices: Beth Stein, MD, on Implications of Newly Approved Pre-Filled Syringe Option for Efgartigimod

The director of neuromuscular diseases at St. Joseph’s Health, shared insights on the impact of a newly approved pre-filled syringe formulation of efgartigimod, highlighting its potential to transform care delivery.

5: Harnessing Gamma Frequencies to Modulate Alzheimer Pathology: Ralph Kern, MD, MHSc

The chief medical officer at Cognito Therapeutics provided a clinical overview on promising findings surrounding the company’s gamma sensory stimulation device in patients with Alzheimer disease. [WATCH TIME: 10 minutes]